EUR 2.72
(-2.01%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 211.75 Million EUR | 37.88% |
2022 | 134.27 Million EUR | -51.53% |
2021 | 277.05 Million EUR | 74.58% |
2020 | 158.7 Million EUR | 78.45% |
2019 | 88.93 Million EUR | 30.87% |
2018 | 67.95 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 43.46 Million EUR | 5.36% |
2024 Q1 | 44.92 Million EUR | -14.64% |
2023 Q2 | 53.7 Million EUR | 13.87% |
2023 FY | 185.14 Million EUR | 37.88% |
2023 Q1 | 47.15 Million EUR | -12.14% |
2023 Q4 | 52.62 Million EUR | 12.66% |
2023 Q3 | 46.71 Million EUR | -13.01% |
2022 Q3 | 39.51 Million EUR | 2.14% |
2022 Q2 | 38.68 Million EUR | 1505.81% |
2022 Q1 | 2.4 Million EUR | 110.35% |
2022 FY | 134.27 Million EUR | -51.53% |
2022 Q4 | 53.67 Million EUR | 35.84% |
2021 Q1 | 110.1 Million EUR | 109.32% |
2021 Q3 | 57.41 Million EUR | -56.78% |
2021 Q2 | 132.82 Million EUR | 20.64% |
2021 FY | 277.05 Million EUR | 74.58% |
2021 Q4 | -23.28 Million EUR | -140.55% |
2020 Q4 | 52.6 Million EUR | 31.67% |
2020 Q3 | 39.94 Million EUR | 4.71% |
2020 Q2 | 38.14 Million EUR | 82.89% |
2020 Q1 | 20.85 Million EUR | -36.36% |
2020 FY | 158.7 Million EUR | 78.45% |
2019 Q1 | 17.32 Million EUR | 0.0% |
2019 Q3 | 13.24 Million EUR | 0.0% |
2019 FY | 88.93 Million EUR | 30.87% |
2019 Q4 | 32.77 Million EUR | 147.51% |
2018 FY | 67.95 Million EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
BioNTech SE | 2.52 Billion EUR | 91.626% |
Biotest Aktiengesellschaft | 136.8 Million EUR | -54.791% |
Biotest Aktiengesellschaft | 136.8 Million EUR | -54.791% |
BRAIN Biotech AG | 24.94 Million EUR | -749.02% |
Formycon AG | 23.73 Million EUR | -792.234% |
Heidelberg Pharma AG | 27.81 Million EUR | -661.27% |
Medigene AG | 20.54 Million EUR | -930.935% |